

Individual psychological therapy for bipolar disorder and substance use

Submission date

28/09/2007

Recruitment status

No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date

28/09/2007

Overall study status

Completed

☐ Statistical analysis plan

☒ Results

Last Edited

10/09/2012

Condition category

Mental and Behavioural Disorders

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Christine Barrowclough

Contact details

Academic Division of Clinical Psychology

2nd Floor, ERC

Wythenshawe Hospital

Manchester

United Kingdom

M23 9LT

+44 0161291 5883

christine.barrowclough@man.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0133190185

Study information

Scientific Title

Study objectives

Is a psychological treatment comprising motivational interviews and cognitive behaviour therapy feasible in terms of acceptability and retention of participants?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Mental and Behavioural Disorders: Bipolar disorders

Interventions

Purpose:

To explore the feasibility of a psychological treatment, (motivational interviews (MI) and cognitive behaviour therapy (CBT)), on substance use and clinical outcome in bipolar patients. The study aims to establish the feasibility of using the therapeutic integration of MI and CBT for this patient group. Participants with the dual diagnosis of bipolar disorder and substance use will be recruited for this research and form two groups, one group receiving standard psychiatric care and the other psychiatric care and psychological therapy.

Bipolar disorder (BD) is a devastating mental illness characterised by a recurring relapsing course, high risk of self harm and suicide (1-3), and considerable subclinical psychopathology outside full episodes (4, 5). The World Health Organization has identified bipolar disorder as the 6th leading cause of disability adjusted life years in the world among people aged 15-44 years (6), and estimated total costs to the UK per annum amount to approximately £2 billion (7). Lithium is an effective drug in prophylaxis, but fails to help about 20-40% of bipolar patients (8-11). The disorder is characterised by high rates of

substance misuse, with studies in psychiatric and community settings reporting rates of 48-70% (12, 13). Such substance misuse can have profound effects on mood and behaviour which worsen the course, outcome and morbidity of bipolar disorder (14). For example, drugs and alcohol may disrupt sleep and circadian rhythms (15, 16), which can worsen prodromal symptoms and hence increase risk of relapse (17, 18). Furthermore, impulsiveness, which has been shown to be particularly elevated in bipolar patients with co morbid substance abuse (19), has been proposed as a possible factor in the significantly poorer treatment outcome and increased risks of suicide and violence observed in individuals with co morbid substance misuse compared to those bipolar disorder alone (14, 20, 21). Despite the high prevalence of substance use in bipolar disorder and its associated risks for illness complications, it has received very little attention within this diagnostic group.

Design:

As an exploratory study for a future definitive trial, the key questions of this study concern the feasibility and potential benefits of the new intervention in addition to standard care. Bipolar patients with co morbid substance misuse will receive individual psychological therapy plus standard psychiatric care or standard psychiatric care alone. A placebo control group is neither practical nor appropriate for a study of this scale.

The key issues to be addressed are; whether this intervention can be delivered and assessed appropriately with this group of patients; how outcome might optimally be measured and indicators of the potential benefits and costs of the proposed therapy.

Method:

The recruitment phase will benefit from the patient identification and recruitment systems established by the MIDAS trial (www.midastrial.ac.uk), in conjunction with the Mental Health Research Network. Recruitment will take place during the first nine months of the study. 20 participants, 10 randomised to each arm of the study will be recruited from three mental health trusts in the Manchester area:

1. Pennine Care NHS Trust
2. Bolton, Salford and Trafford Mental Health Partnership Trust
3. Nottinghamshire Healthcare NHS Trust

Identifying potential participants:

All sites within the two trusts will be approached about the trial at the same stage. The research team aim to establish good liaisons with participating sites and services and ensure clinicians are well informed about the study and how to refer potential participants.

Eligible Participants:

Where permission is given eligible participants will be approached and introduced to the study by either the research assistant or care coordinator, depending on the preference of the care coordinator. Each potential participant in the community will be contacted by letter or telephone informing them in brief about the research and to arrange a time for the research assistant to visit them and introduce the study. All written correspondence, including consent forms and information sheets, will be written on headed paper and have contact information for the relevant research assistant. After the initial meeting potential participants will be given at least 24 hours to consider participation and will then be contacted by the research assistant (in a way agreed by the participant) to establish if they wish to take part in the study. The research assistant will visit each Potential participant interested in the study so that written consent can be obtained. Once participants have consented in writing an assessment for inclusion in the trial will be carried out using the SCID (a structured clinical interview) to confirm diagnosis. All potential participants will be assessed according to DSM-IV criteria for bipolar disorder; in addition patients will be interviewed concerning drug and alcohol use on the basis of the

relevant SCID screening sections and regarding use in the preceding three months. Participants will be informed about their eligibility for the study and will be randomly allocated to the control group (treatment as usual) or the experimental group which involves treatment as usual plus the additional psychological therapy which is an integration of Motivational Interviews (MI) and Cognitive Behaviour Therapy (CBT). Therapy sessions will be offered in participants preferred location (NHS setting or home) to facilitate attendance. Participants in the experimental group will receive up to 26 therapy sessions over 12 months which will comprise of a one hour session every two weeks. Given the nature of the participants, the trial will be as flexible as time scales permit in offering additional appointments following periods of non-attendance. The follow-up period will be 10 months from initial randomisation into groups (patients will begin treatment within 2 weeks of randomisation). In addition to the therapy sessions participants will have regular assessments to evaluate bipolar relapse and substance use every three months as well as detailed assessment of social rhythms and activity, using the Social rhythm metric which records daily activity patterns over week long periods (22). Participants will also be asked to wear actiwatchers for the initial week of the study and the final week of the study. Actiwatchers are a non-invasive objective measure of activity using actigraphy (23, 24). Participants will be asked to complete the Beck depression inventory (BDI) and internal states scale (ISS) which will measure changes in mood. Reduction in impulsivity will be measured with the Barratt impulsiveness scale, a validated self report measure which has identified elevated impulsiveness in bipolar disorder and substance use (19). The additional psychological intervention (MI and CBT) is used to facilitate engagement and explore the role of substance misuse in worsening symptoms of bipolar disorder. Information collected will be used to create an individualised formulation identifying links between substance misuse and destabilisation. This will form the basis of a Cognitive Behaviour Therapy intervention focused on changing drug use behaviour and developing a comprehensive relapse prevention plan.

Treatment Integrity:

Independent evaluation of therapy will be conducted by an independent rater who will listen to 10% of therapy tapes to assess for fidelity and competence. The California Psychotherapy Alliance Scale will be used as a measure of alliance and the Motivational Interviewing Treatment Integrity code will be used to assess motivational interviewing skills. Treatment dose (frequency and duration) will be closely monitored.

Timetable:

0-4 months: recruit participants, assessment of participants

4-11 months: treatment phase - additional psychological intervention (26 fortnightly sessions) and monthly assessments

12-15 months: collate data, develop and maintain database

15-17 months: follow up assessments, data entry for follow-up

17-24 months: analysis of data, write scientific report

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

The feasibility of a psychological treatment comprising of motivational interviews and cognitive behaviour therapy, in terms of acceptability for this patient group and retention of participants. Effect size for therapy outcomes will be determined to so that a definitive trial can be planned

which is appropriately powered with respect to the primary outcome measures. Primary Therapy Outcome Measures: number of bipolar relapses and frequency and severity of substance misuse.

Secondary outcome measures

Measures of bipolar symptomatology and time to relapse will be estimated. Also, in line with the key targets of the planned intervention, we will assess stabilisation of social rhythms and reduction in impulsiveness as a result of treatment. Self report vs collateral outcome measures will be compared for the assessment of time to bipolar relapse, frequency and duration of relapse and severity and frequency of substance misuse. Comparisons will be made with respect to completeness of data sets in each case and will indicate the most appropriate outcome measures to use for a definitive trial.

Overall study start date

16/01/2007

Completion date

02/01/2009

Eligibility

Key inclusion criteria

1. Bipolar inclusion criteria will be as follows: bipolar disorder I or II according to DSM-IV criteria and not meeting current episode criteria for mania or major depression
2. Substance use inclusion criteria are: alcohol and/or substance abuse or dependence according to DSM-IV criteria, alcohol use exceeding 28 units for males/21 units for females on at least half of the weeks of the previous 3 months and/or use of illicit drugs on at least two days per week in at least half the weeks in the 3 months prior to assessment
3. General inclusion criteria includes: current contact with mental health services, all participants will be 18 years or older, have no evidence of organic brain disease or learning disability, not be currently actively suicidal, they must be able to provide informed consent and having a fixed abode

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

20

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

16/01/2007

Date of final enrolment

02/01/2009

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Academic Division of Clinical Psychology

Manchester

United Kingdom

M23 9LT

Sponsor information

Organisation

Record Provided by the NHSTCT Register - 2007 Update - Department of Health

Sponsor details

The Department of Health, Richmond House, 79 Whitehall

London

United Kingdom

SW1A 2NL

+44 (0)20 7307 2622

dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type

Government

Funder Name

Bolton, Salford and Trafford Mental Health NHS Trust (UK)

Funder Name

NHS R&D Support Funding

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2011		Yes	No